Dermatol. praxi. 2022;16(3):167-170 | DOI: 10.36290/der.2022.034

Current Role of 5-fluorouracil in the Treatment of Actinic Keratosis

doc. MUDr. Jiří Slíva, Ph.D.
Ústav farmakologie, 3. LF UK, Praha

Actinic keratosis is the most common skin precancerosis that occurs on skin damaged by chronic exposure to ultraviolet radiation, hence the synonym "solar keratosis". The range of treatment options is relatively strict, but in addition to surgery and cryotherapy, it includes topical pharmacotherapy. The article summarizes the basic observations of the treatment options and focuses mainly on the benefits of 5-fluorouracil in 5% and the innovative 4% form of the cream.

Keywords: actinic keratosis, pharmacotherapy, treatment, 5-fluorouracil, cancer, tolerability.

Accepted: October 11, 2022; Published: October 17, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Current Role of 5-fluorouracil in the Treatment of Actinic Keratosis. Dermatol. praxi. 2022;16(3):167-170. doi: 10.36290/der.2022.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Criscione VD, Weinstock MA, Naylor MF et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115(11):2523-2530. Go to original source... Go to PubMed...
    2. Madani S, Marwaha S, Dusendang JR, et al. Ten-Year Follow-up of Persons With Sun-Damaged Skin Associated With Subsequent Development of Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2021;157(5):559-565. Go to original source... Go to PubMed...
    3. Heppt MV, Leiter U, Steeb T, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges. 2020;18(3):275-294. Go to original source... Go to PubMed...
    4. Piquero-Casals J, Morgado-Carrasco D, Gilaberte Y, et al. Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization. Dermatol Ther (Heidelb). 2020;10(5):903-915. Go to original source... Go to PubMed...
    5. Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017;28(5):431-442. Go to original source... Go to PubMed...
    6. Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85(4):e209-e233. Go to original source... Go to PubMed...
    7. Figueras Nart I, Cerio R, Dirschka T, et al. Defining the actinic keratosis field: a literature review and discussion. J Eur Acad Dermatol Venereol. 2018;32(4):544-563. Go to original source... Go to PubMed...
    8. Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S28-38. Go to original source... Go to PubMed...
    9. Dushinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropyrimidines. J Am Chem Soc. 1957;79:4559-4560. Go to original source...
    10. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001;23(6):908-920. Go to original source... Go to PubMed...
    11. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 Suppl):22-29.
    12. Gupta AK, Paquet M. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013;169(2):250-259. Go to original source... Go to PubMed...
    13. Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized Trial of Four Treatment Approaches for Actinic Keratosis. N Engl J Med. 2019;380(10):935-946. Go to original source... Go to PubMed...
    14. Jansen MHE, Kessels JPHM, Merks I, et al. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands. Br J Dermatol. 2020;183(4):738-744. Go to original source... Go to PubMed...
    15. Ezzedine K, Painchault C, Brignone M. Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses. Acta Derm Venereol. 2021;101(1):adv00358. Go to original source... Go to PubMed...
    16. Dohil MA. Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared With 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis. J Drugs Dermatol. 2016;15(10):1218-1224. Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.